Arcturus Therapeutics Issues Open Letter to Shareholders
Details Former President and CEO Joseph E. Payne’s Poor Judgment, Failed Leadership and Deceit that Led to His Termination for Cause
Cites Payne’s Self-Dealing and Blatant Disloyalty to Arcturus, its Shareholders and Collaborators
The full text of the letter follows:
Dear Fellow Shareholder,
The future value of your Arcturus investment is at risk because
We want to set the record straight – Payne’s misconduct, poor judgment and failed leadership led to his termination as CEO in January. Indeed, our ongoing investigation continues to reveal additional details surrounding Payne’sconcerted attempts to deceive, manipulate and lie to Arcturus shareholders, partners and other stakeholders, including:
- Payne’s repeated efforts to transfer valuable intellectual property rights from the Company to Providence Therapeutics for no additional consideration or benefit to Arcturus and its shareholders; and
- Payne’s undisclosed, unauthorized and lucrative side business, on which he spent substantial time and energy operating during Arcturus business hours for nearly three years, while neglecting his responsibilities and duties to Arcturus.
The facts are clear: Payne consistently abused his authority, and continues to demonstrate a willingness to mislead shareholders for his own personal and financial gain. Had we known the extent of Payne’s egregious behavior earlier, we would have taken steps to terminate him much sooner.
Yesterday, we initiated a lawsuit against Payne, outlining his track record of collusion, deceit and self-dealing. The lawsuit seeks to hold Payne accountable to the Company and its shareholders for damages caused by his breaches of contract and fiduciary duties. The complaint details evidence of significant conflicts of interest, violations of trust and Payne’s willingness to exploit Arcturus and its shareholders to benefit himself and a small sub-group of Arcturus shareholders, including his lifelong personal friends. We will continue to take the appropriate and decisive actions necessary to protect your investment in Arcturus and the future of the Company.
Arcturus will hold its extraordinary general meeting of shareholders on
PAYNE’S POOR JUDGMENT, BAD DECISIONS AND INEFFECTIVENESS AS A CEO
It is important for all shareholders to understand Payne’s actions as CEO of ATI, the privately-held entity that merged with Alcobra in
Although members of the ATI Board had questions regarding Payne’s experience, judgment and ability to make responsible decisions on behalf of the Company, they had limited recourses to proactively address these questions because of Payne’s rogue decision-making process. For example, Payne approached and retained an investment bank about a potential IPO, against the recommendation of the independent directors who believed that the Company was not at a suitable stage to go public. Payne then inexplicably failed to terminate the investment banking retention agreement, despite significant fees being incurred by the Company. When the Board became aware of the situation, two of the independent directors stepped in and terminated the agreement. This highlights Payne’s lack of attention, lack of understanding of the IPO process and inexperience with public companies, which he continued to demonstrate through questionable judgment calls.
PAYNE’S MANIPULATION, DECEIT AND SELF-DEALING:
TAKING THE FIRST AND LAST DOLLAR FOR HIMSELF AT THE EXPENSE OF SHAREHOLDERS
Payne’s Attempt to Transfer Shareholder Value to Lifelong Personal Friends
Prior to the ATI / Alcobra merger, Payne twice attempted to force the Board to approve an amendment to the existing Joint Venture agreement between ATI and Providence Therapeutics, as requested by
The amendment had no business rationale, provided no benefits to ATI or later Arcturus, and would have transferred value away from you, Arcturus shareholders, to Payne’s friends for free. Later, Payne attempted to push through approval of Board minutes to falsely reflect an approval of the amendment. Your independent Board members immediately and unanimously disputed this, and ensured that the record was properly stated.
Payne’s misrepresentation regarding the amendment’s approval had serious ramifications for the Company and its Board. On
The dispute over the value destructive
Our investigation has also uncovered evidence of suspicious trading activity prior to several recent key announcements from the Company, including Sorenson’s trades in Arcturus securities that took place the day before the announcement of our strategic collaboration with CureVac on
Following repeated requests from Arcturus and our attorneys, we recently received back from Payne his Company-issued-and-paid-for cell phone, more than two months following his termination. The device had been reset to its factory settings, a move by Payne that deleted all information contained on the phone. This raises the question of “what else is Payne hiding from Arcturus and its shareholders?”
PAYNE’S ASSOCIATES AND NOMINEES
Consistent with our commitment to best-in-class corporate governance practices, the Board initiated a process to meet with Payne’s four proposed nominees. Following outreach efforts led by the Chair of our Nominating Committee, we have not received any responses. As an initial step, we identified concerns with at least one of the nominees based on preliminary research, including a report from a well-respected national publication regarding the nominee’s abusive workplace behavior. These concerns underscore the importance of meeting with Payne’s nominees to evaluate their qualifications and fitness for a seat on the Arcturus Board. As we have previously stated, we cannot proceed if the nominees do not respond to our requests for meetings with them.
TO MAKE AN INFORMED DECISION AT THE UPCOMING EXTRAORDINARY GENERAL MEETING
SHAREHOLDERS NEED TO KNOW ABOUT THE REAL
|Payne shirked his responsibilities as President and CEO||Payne operated an undisclosed, unauthorized and lucrative side business out of Arcturus’ offices and during business hours, in which he acted as a vendor selling products, including a substance called Ionophore, to various corporate buyers, in violation of his employment agreement.
Payne recruited at least two ATI executives in his scheme, and used his position as CEO to negotiate more favorable terms for these personal transactions.
|Payne was a weak CEO that ignored the Board’s important oversight role and perspectives||On numerous occasions, Payne withheld important information from the rest of the Board regarding the Company’s collaborations with various partners. Although Payne learned that there were serious problems with these partnerships over the course of 2017, Payne did not appropriately communicate these problems to the Board, and Payne did nothing himself to fix them.|
Despite his continuing fiduciary duties as a Company Director, Payne continues to put Arcturus and our shareholders at significant risk through a vindictive campaign of interference and sabotage fueled by spite. His actions recently resulted in the rejection of an otherwise routine proposal to appoint new independent auditors – the same firm that effectively audited ATI for years prior to the merger with Alcobra. This has delayed the filing of our financial results and has the potential to expose Arcturus to serious consequences including potential delisting from NASDAQ.
ARCTURUS’ DIRECTOR NOMINEESARE EXPERIENCED, RESPECTED AND COMMITTED TO PROTECTING SHAREHOLDERS’ RIGHTS AND INTERESTS
Arcturus has a highly qualified and actively engaged Executive Committee of the Board comprised of respected and proven leaders with decades of management experience. Collectively, the Company’s Board brings a wide variety of healthcare, drug development and commercialization, and financial expertise that is critical to Arcturus’ business.
The Executive Committee of Arcturus’ Board unanimously recommends shareholders vote “FOR” Proposals 4, 5 and 6 at the Extraordinary General Meeting of Shareholders on
- Proposal 4: Approval of the removal of Mr.
Joseph Paynefrom his role as a Director on Arcturus’ Board, with immediate effect.
- Proposal 5: Ratification of the appointment of
Ernst & Young LLPas Arcturus’ independent auditors for the audit of Arcturus’ financial statements for the year ended December 31, 2017and for the additional period until Arcturus’ annual meeting of shareholders in 2018.
- Proposal 6: To approve the adjournment or postponement of the EGM until a later date, time and venue as determined by the chairperson of the EGM (subject to any required notification under Israeli law).
The Executive Committee of your Board is committed to doing what is necessary to protect Arcturus’ rights and the interests of our shareholders and other stakeholders.
The Executive Committee of Arcturus’ Board of Directors
If investors have any questions, please contact the Company’s proxy solicitor:
Stockholders Call Toll Free: (800) 662-5200
Additional Information and Where to Find It
In connection with the meeting, Arcturus will make available to its shareholders of record a proxy statement describing the time and place for, and other logistical information related to, the meeting and the proposal to be voted upon at the meeting, along with a WHITE proxy card enabling them to submit their votes on that proposal. Arcturus will also be furnishing copies of the proxy statement and WHITE proxy card to the
The full text of the proposed resolution for the meeting, together with the form of the WHITE proxy card, may also be viewed beginning on
Founded in 2013 and based in
This press release may contain “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, collaborations, future financial position, prospects, plans and objectives of management are forward-looking statements. Examples of such statements may include, but are not limited to, statements relating to the expectations regarding voting by Arcturus’ shareholders. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements and you should not place undue reliance on those forward-looking statements. Any such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in any forward-looking statements.
The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ (formerly Alcobra Ltd.’s) Annual Report on Form 20-F for the fiscal year ended
Morrow Sodali, LLC
Source: Arcturus Therapeutics, Inc.